Cost-effectiveness analysis of triple therapy Budesonide/ Glycopyrronium/ Formoterol fumarate versus dual therapies LAMA/LABA and ICS/LABA in COPD patients from the perspective of the Spanish National Health System.
This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.